Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1217"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_assump_list_id |
"210"
|
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:claim_assumed_valid_for_evidence_application_evidence_1840 | |
| ?:content |
"route of administration: oral
study duration: On day 1, subjects received a single 100-mg dose of desvenlafaxine or 75-mg dose of venlafaxine ER, followed by 120 hours of pharmacokinetic sampling. Subjects fasted over night for at least 10 hours before the required blood sample collection and administration of test article. Study treatment washout occurred between study days 7 and 9. On day 11, the alternate treatment was administered (ie, either a single 100-mg dose of desvenlafaxine or 75-mg dose of venlafaxine ER), followed by 120 hours of pharmacokinetic sampling, under the same conditions described for day 1. On study day 16, subjects completed the study.
population: non-smokers (> 1 year)
tested for known CYP450 polymorphisms? seven participants were found to be CYP2D6 extensive metabolizers and seven were found be be CYP2D6 poor metabolizers based on genotyping. They excluded intermediate and ultra metabolizers.
ages: 18 - 55
description:
The mean Cmax and AUC for venlafaxine after administration of venlafaxine ER were significantly higher, by approximately 149% and 331%, respectively, in PM subjects compared with EM subjects (P = 0.001)"
|
| dc:creator | |
| dc:date |
"09/25/2009 11:00:03"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ venlafaxine_primary_total_clearance_enzyme_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1840 }